Literature DB >> 11197241

Characteristics of adult celiac disease in the USA: results of a national survey.

S N Stavropoulos, S G Panagi, S L Goldstein, D J Mcmahon, H Absan, A I Neugut.   

Abstract

OBJECTIVE: The clinical spectrum of adults with celiac disease in the United States, where the disease is considered rare, is not known. We sought this information by distributing a survey.
METHODS: A questionnaire was distributed by way of a celiac newsletter, directly to celiac support groups, and through the Internet.
RESULTS: Respondents (1,612) were from all United States except one. Seventy-five percent (1,138) were biopsy proven. Women predominated (2.9:1). The majority of respondents were diagnosed in their fourth to sixth decades. Symptoms were present a mean of 11 yr before diagnosis. Diarrhea was present in 85%. Diagnosis was considered prompt by only 52% and 31% had consulted two or more gastroenterologists. Improved quality of life after diagnosis was reported by 77%. Those diagnosed at age > or = 60 yr also reported improved quality of life. Five respondents had small intestinal malignancies (carcinoma 2, lymphoma 3) accounting for a relative risk of 300 (60-876) for the development of lymphoma and 67 (7-240) for adenocarcinoma.
CONCLUSIONS: Patients with celiac disease in the United States have a long duration of symptoms and consider their diagnosis delayed. Improved quality of life after diagnosis is common. An increased risk of developing small intestine malignancies is present.

Entities:  

Mesh:

Year:  2001        PMID: 11197241     DOI: 10.1111/j.1572-0241.2001.03462.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  132 in total

1.  Presentations of adult celiac disease in a nationwide patient support group.

Authors:  Robert D Zipser; Sunil Patel; Kareem Z Yahya; Donald W Baisch; Elaine Monarch
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

2.  European and North American populations should be screened for coeliac disease.

Authors:  A Fasano
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

3.  Coeliac disease: is case finding the correct ethical and logistical approach?

Authors:  D S Sanders
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

4.  Changing presentation of adult celiac disease.

Authors:  Winson Lo; Kevin Sano; Ben Lebwohl; Beverly Diamond; Peter H R Green
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

Review 5.  Celiac disease in Middle Eastern and North African countries: a new burden?

Authors:  Kassem Barada; Abbas Bitar; Mohamad Abdul-Razak Mokadem; Jana Ghazi Hashash; Peter Green
Journal:  World J Gastroenterol       Date:  2010-03-28       Impact factor: 5.742

6.  Procedure volume influences adherence to celiac disease guidelines.

Authors:  Benjamin Lebwohl; Robert M Genta; Robert C Kapel; Daniel Sheehan; Nina S Lerner; Peter H Green; Alfred I Neugut; Andrew Rundle
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-11       Impact factor: 2.566

7.  Gluten intolerance: sex and age-related features.

Authors:  M J Llorente-Alonso; M J Fernández-Acenero; M Sebastián
Journal:  Can J Gastroenterol       Date:  2006-11       Impact factor: 3.522

8.  Antibody negative coeliac disease presenting in elderly people--an easily missed diagnosis.

Authors:  David S Sanders; David P Hurlstone; Mark E McAlindon; Marios Hadjivassiliou; Simon S Cross; Graeme Wild; Christopher J Atkins
Journal:  BMJ       Date:  2005-04-02

9.  Increased risk for non-Hodgkin lymphoma in individuals with celiac disease and a potential familial association.

Authors:  Ying Gao; Sigurdur Y Kristinsson; Lynn R Goldin; Magnus Björkholm; Neil E Caporaso; Ola Landgren
Journal:  Gastroenterology       Date:  2008-09-25       Impact factor: 22.682

10.  Celiac disease in patients with presumed irritable bowel syndrome: a case-finding study.

Authors:  Khaled Ali Jadallah; Yousef Saleh Khader
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.